J&J's Esketamine, at current price, is 'low value for money' — ICER
For Johnson & Johnson’s $JNJ pharmaceutical version of the hallucinogenic anesthetic ketamine — esketamine — to be cost-effective for use in treatment-resistant depression in the long term, its list price must be cut by up to half, ICER concluded in its final report on Thursday.
Cognizant of the myriad of approved antidepressants that often don’t work, the US regulator endorsed J&J’s esketamine, branded as — Spravato — in March for treatment-resistant depression, conscious that the original cat tranquilizer is frequently used off-label for severe depression.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
